ハイスループット・スクリーニング(HTS)の欧州市場の戦略分析

Research Overview

High Throughput Drug Screening - Allaying Risks Associated with Drug Discovery

The development of effective drugs remains a challenging, risky and expensive endeavour. High throughput drug screening (HTS) is emerging as a saviour in the field of drug discovery as pharmaceuticals and biotechnology companies compete to become the first to market new drugs. By shortening the drug discovery cycle, HTS offers the opportunity to capture the maximum market share and optimise revenue generation within the first year of entry. HTS also increases the chances of clearing clinical trials by addressing issues related to pharmacokinetics, animal toxicity and side effects. In spite of high equipment costs and poor quality of lead compounds presenting a significant challenge, HTS has the potential to yield both mechanistic insights and new drug leads with unparalleled efficiency through investment and innovation.

This Frost & Sullivan research evaluates the key drivers and challenges in the European HTS market. It also examines the important technology trends and provides strategic recommendations for designing high-impact action plans.

Outsourcing HTS to Custom Screeners Proving Extremely Cost-effective

Outsourcing HTS has emerged as a cost-effective option for multinational pharmaceuticals and biotechnology companies that are under pressure to discover and develop new therapeutics at lesser costs and within shorter time frames. Research indicates that approximately 10 per cent of the funds allocated to early stage discovery are accounted for by outsourcing. "Outsourcing not only compresses the time line for drug development and reduces the overall costs, it also provides access to additional drug entities and innovative technology," explains the analyst of this research.

Market for HTS is Expanding

The HTS field continues to be highly dynamic and competitive. "Information sharing between competing companies, coupled with open technology transfer meetings and publications, has greatly accelerated the development of the HTS industry," says the analyst. The success of genomic and proteomic searches provides a more comprehensive list of cellular targets. The anticipated use of functional genomics and proteomics to bridge the gap between physical-chemical activities and the drug development process is also expected to be a major driver in the HTS market.

Frost & Sullivan Growth Partnership Service

Based on extensive and in-depth research, real-world consulting work, and new theories tested in hundreds of companies across many industries, Frost & Sullivan has evolved its Growth Partnership Services (GPS) programme that provides established and emerging firms with powerful growth visions. Moving beyond token mission statements, GPS provides an actionable vision to growth consulting partners by illustrating how key intelligence and strategic research based on defined goals can guide day-to-day behaviour and overall company direction. The foundation of Frost & Sullivans GPS includes:

• Assisting companies to reach their full potential in the core business
• Providing growth strategies to help companies expand into related businesses
• Preemptively redefining the core business during market turbulence
• Applying the Frost & Sullivan framework to identify and address common mistakes resulting from misaligned corporate strategies
• Recommending growth management strategies through continuous partnership

To maximise the potential for growth within a firms internal and external environment, Frost & Sullivan consultants can facilitate the creation of strategic programmes that deliver improved market success. Frost & Sullivans strengths lie in combining strategic understanding with market expertise and applying these with absolute commitment to its clients growth.

1 STRATEGIC ANALYSIS OF THE EUROPEAN HIGH THROUGHPUT SCREENING MARKET

• Overview
  • Overview
• Research Scope & Methodology
  • Research Scope & Methodology
• Introduction & Background
  • Introduction & Background
• Market Dynamics
  • Key Market Trends
  • Market Drivers
  • Market Restraints
  • Industry Challenges
  • Key Technology Trends
  • Technology Drivers
  • Technology Restraints
• Total Market Forecasts
  • Assumptions
  • Total Revenue Forecasts
  • Revenue Analysis
  • Key Market Engineering Measurements
  • Revenue Trends By Geographical Region
  • Total Drug Development Expenditure
  • Drug Discovery Market Share By Geographical Region
  • Company Profiles
• Strategic Analysis & Recommendations
  • Market Maturation Process
  • Strategic Anticipation
  • Potential Threats
  • Competitive Framework
  • Market Potential
  • Three Levels Of Strategies
  • Pricing Strategy
  • What Can Be Expected in the Future?
  • Meeting the Challenge
• Frost & Sullivan Awards
  • Frost & Sullivan Awards
  • Competitive Strategy Leadership Award
  • Customer Service Innovation Award
  • Market Leadership Award
  • Technology Innovation Award
  • Growth Strategy Leadership Award
• Industry Participants
  • Industry Participants
• Decision Support Databases
  • Decision Support Databases
• Frost & Sullivan
  • Healthcare Team
  • Our Capabilities